Redeye provides a research update following the Q4 2024 report from Catella. Adjusting for one-off restructuring costs, Investment Management showed performance just slightly shy of estimates, and Corporate Finance delievered impressive cost control with a markedly higher EBIT than foreseen. In Principal Investments, Polaxis was divested with a slight profit, and we continue to argue that the Kaktus divestment will play a key part in closing the gap between our Base Case and the current share price. With a change of lead analyst and a reworked valuation approach, Redeye mostly maintains its fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/